0000000000736196

AUTHOR

Giovanni Francesco Pellicanò

0000-0002-9640-8742

showing 2 related works from this author

Factors Associated With Weight Gain in People Treated With Dolutegravir.

2020

AbstractBackgroundAn unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens.MethodsAdult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between July 2014 and December 2019 in the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were included. We used an adjusted general linear model to compare weight change among backbone groups and a Cox proportional hazard regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for …

0301 basic medicinemedicine.medical_specialtyWeight gain.HIV metabolic complications030106 microbiologyHIV metabolic complicationTDFEmtricitabineTenofovir alafenamidedolutegravir HIV metabolic complications TAF TDF weight gain.03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAbacavirInternal medicinemedicineMajor Article030212 general & internal medicinebusiness.industryWeight changeLamivudineweight gaindolutegravirInfectious DiseasesAcademicSubjects/MED00290OncologychemistryTAFRilpivirineDolutegravirmedicine.symptombusinessWeight gainmedicine.drugOpen forum infectious diseases
researchProduct

Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

2021

This study evaluates the frequency and causes of dolutegravir (DTG) discontinuation along 5 years of follow-up, in both antiretroviral treatment (ART)-naive and experienced people living with HIV (PLWH). This is a prospective multi-center cohort study enrolling PLWH on DTG from July 2014 until November 2020. DTG-durability was investigated using the Kaplan-Meier survival curve. The Cox proportional-hazards model was used for estimating the hazard ratio (HR) of DTG discontinuation for any cause, and for adverse events (AEs). Nine hundred sixty-three PLWH were included, 25.3% were women and 28.0% were ART-naive. Discontinuations for any causes were 10.1 [95% confidence interval (95% CI) 8.9-1…

adverse events; dolutegravir; durability; HIV; safety; toxicity; virolgical failure; Cohort Studies; Female; Heterocyclic Compounds 3-Ring; Humans; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Anti-HIV Agents; HIV InfectionssafetyPediatricsmedicine.medical_specialtySettore MED/17 - Malattie InfettivePyridonesAnti-HIV AgentsOxazineHuman immunodeficiency virus (HIV)adverse eventHIV Infectionsvirolgical failurePyridonemedicine.disease_cause3-RingHIV Infections.PiperazinesCohort Studieschemistry.chemical_compoundHeterocyclic CompoundsHIV; adverse events; dolutegravir; durability; safety; toxicity; virolgical failureOxazinesAntiretroviral treatmentMedicineHumansProspective StudiesAdverse effectPiperazinebusiness.industryPublic Health Environmental and Occupational HealthHIVtoxicityAnti-HIV AgentMiddle Agedadverse eventsDiscontinuationdolutegravirvirolgical failure.Prospective StudieInfectious DiseaseschemistryDolutegravirdurabilityObservational studyFemaleCohort StudiebusinessHeterocyclic Compounds 3-RingHuman
researchProduct